|
Orthologous residues
|
|
MFN2 (human): S27‑p, MFN2 (mouse): S27‑p, MFN2 (rat): S27‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
JNK2 iso2 (human)
|
co-immunoprecipitation, siRNA inhibition of enzyme, transfection of constitutively active enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
doxorubicin
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
protein degradation, ubiquitination
|
|
Effect of modification (process):
apoptosis, induced
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
HUWE1 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|
|
Comments:
HUWE1 associates with Mfn2, and leads to Its ubiquitination and degradation.
|
